Table 1.
Baseline Characteristics
| Autologous HCT (n=28) | Allogeneic HCT (n=20) | |
|---|---|---|
| Age, years (median, range) | 69.9 (50.3 – 79.5) | 68.8 (51.4 – 76.6) |
| Female gender (n, %) | 14 (50) | 9 (45) |
| Transplant diagnosis (n, %) | Multiple Myeloma, 12 (43) NHL, 16 (57) |
AML/MDS, 13 (65) HL and NHL, 7 (35) |
| Disease Status | ||
| CR/VGPR/PR | 25 (89) | 13 (65) |
| Stable/Progressive disease | 3 (11) | 7 (35) |
| HCT-CI | ||
| 0-2 | 10 (36) | 7 (35) |
| ≥3 | 18 (64) | 13 (65) |
| Clinician-assessed KPS | ||
| ≥90 | 12 (43) | 6 (30) |
| <90 | 16 (57) | 14 (70) |
| Conditioning intensity | ||
| Myeloablative | 28 (100) | 8 (40) |
| RIC/NMA | 0 (0) | 12 (60) |
Abbreviations: HCT, Hematopoietic cell transplant; AML/MDS, Acute myeloid leukemia/Myelodysplastic Syndrome; NHL, Non-Hodgkin’s Lymphoma; HL, Hodgkin’s Lymphoma; CR/VGPR/PR, Complete response/Very good partial response/Partial response; HCT-CI, Hematopoietic cell transplant-comorbidity index; KPS, Karnofsky Performance Scale; RIC/NMA, Reduced-intensity/non-myeloablative conditioning.